Meet Dr Jane Smith: improving lung cancer survival rates

Lung cancer remains one of the most serious health challenges in Australia, with outcomes shaped by tumour biology, stage at diagnosis, access to treatment, and the support available after care begins. For Dr Jane Smith, improving survival rates means addressing each of these factors through research that can make a measurable difference in everyday clinical practice.

Dr Smith’s work brings together early detection, personalised treatment, and coordinated care. Her approach reflects the purpose of health translation: moving discoveries from laboratories and data sets into services that help patients, families, carers, and communities live longer and with a better quality of life.

This profile explores the research questions guiding her work, the value of collaboration, and the practical steps that can help lung cancer research reach patients sooner. It also reflects the broader role of Brisbane Diamantina Health Partners in connecting researchers, universities, and health services across Queensland.

Finding cancer earlier

Lung cancer is often diagnosed after symptoms have become persistent or advanced. A cough, breathlessness, chest discomfort, fatigue, or unexplained weight loss may be attributed to less serious conditions, delaying referral and investigation. Dr Smith’s research focuses on improving the pathways that help clinicians recognise risk and organise timely diagnostic testing.

Earlier detection depends on more than a single screening tool. It requires clear referral criteria, accessible imaging, rapid reporting, and communication between general practice, respiratory medicine, radiology, pathology, and oncology. Research can identify where patients are lost between these steps and test practical solutions, such as streamlined assessment clinics or digital reminders for follow-up.

Personalising treatment decisions

Lung cancer is not one disease. Different tumour types and molecular features can influence how a cancer behaves and how it responds to surgery, radiotherapy, chemotherapy, immunotherapy, or targeted medicines. Dr Smith’s work examines how clinical information and biomarker testing can support more precise treatment choices.

Personalised oncology also involves understanding the person behind the diagnosis. Age, other chronic conditions, treatment preferences, housing, transport, cultural needs, and family responsibilities may all affect care. A treatment plan is more useful when it is medically appropriate and realistic for the patient’s circumstances.

This is where multidisciplinary teams are essential. Surgeons, oncologists, respiratory physicians, nurses, pharmacists, allied health professionals, pathologists, and Aboriginal and Torres Strait Islander health practitioners can contribute different perspectives. Shared decision-making helps ensure that evidence is translated into care patients understand and can access.

From research findings to clinical practice

A promising laboratory result does not automatically improve survival. Researchers must establish whether an intervention is safe, effective, affordable, and suitable for the health services expected to deliver it. Implementation research helps answer these questions by examining how new evidence works in real clinical environments.

Dr Smith’s approach places patients and clinicians within the research process. Their experiences can reveal barriers that may be invisible in controlled studies, including long travel distances, waiting times, confusing information, or limited access to specialist services. Feedback from consumers can shape research priorities and make study outcomes more relevant.

The same translation principles apply across health disciplines. For example, bench-to-bedside innovation shows how scientific discoveries can be assessed, adapted, and integrated into patient care. Lung cancer research follows a similar pathway, requiring rigorous evidence alongside service design and workforce support.

Measuring what matters to patients

Survival is a vital outcome, but it is not the only measure of successful lung cancer care. Researchers increasingly assess quality of life, symptom control, treatment burden, emotional wellbeing, and a person’s ability to return to valued activities. These patient-reported outcomes can show whether a treatment is helping in ways that standard clinical measures may miss.

Dr Smith’s research also considers the experience of carers and families. They may coordinate appointments, manage medicines, provide transport, and offer emotional support while coping with uncertainty themselves. Better information, psychosocial care, palliative support, and communication can improve the experience of care at every stage.

The table below illustrates how different research priorities can contribute to better outcomes:

Building collaborative health research

Lung cancer research is strongest when it draws on multiple forms of expertise. Universities and research institutes contribute scientific methods, data analysis, and clinical trials. Health services provide access to patients and the practical setting for implementation. Community organisations and consumer representatives help ensure that research responds to lived experience.

Collaboration can also support larger studies and more representative findings. When teams share expertise, infrastructure, and data governance processes, they may be able to answer questions that a single organisation could not address alone. The Brisbane Diamantina network provides a model for bringing these partners together around health priorities.

Sustainable collaboration requires clear agreements about ethics, privacy, authorship, funding, and responsibilities. Investigators developing a new project can also review funding opportunities that support cross-institutional health research in Queensland. Strong governance protects participants and strengthens confidence in the results.

Priorities for the next phase

Improving lung cancer survival rates will require continued investment in prevention, early diagnosis, treatment innovation, and supportive care. Tobacco control remains important, while research must also address lung cancer in people who have never smoked. Environmental exposures, occupational risks, ageing, and health inequities all deserve attention.

Dr Smith’s work demonstrates why clinical research should be connected to the services where patients receive care. A discovery has its greatest value when it can be adopted by a health team, understood by a patient, and sustained over time. Translation is therefore a shared responsibility rather than a final step after research is complete.

Practical priorities for better outcomes

• Expand timely assessment for people with persistent or concerning respiratory symptoms.
• Improve access to molecular and biomarker testing across metropolitan, regional, and rural services.
• Include patients and carers when setting research questions and evaluating new models of care.
• Measure quality of life, symptom burden, and treatment experience alongside survival.
• Build secure partnerships that support ethical data sharing and coordinated clinical trials.

Researcher profiles such as this one help make the process of medical discovery visible. They show how better outcomes emerge through careful questions, patient involvement, collaboration, and persistence across the health system. Dr Jane Smith’s focus on lung cancer illustrates the potential of translation to turn evidence into earlier diagnoses, more suitable treatments, and stronger support for people living with cancer.

Explore Brisbane Diamantina Health Partners’ research themes, partnerships, education, governance, and health news to see how collaborative health research is shaping care in Queensland. Support and share evidence-based approaches that help lung cancer research move closer to the patients who need it.